Sui JD, et al. - Authors compared the incidences of programmed cell death-1 (PD-1) inhibitor-related hematologic toxicities among different therapeutic regimens and tumor types. In RCC higher risks of PD-1 inhibitor-related hematologic toxicities were seen vs in other cancers and during combination therapy. The awareness regarding frequent clinical monitoring when managing PD-1 inhibitors among clinicians was enhanced by the findings. Significantly higher risks for all-grade anemia, thrombocytopenia, leukopenia, neutropenia, and only high-grade thrombocytopenia was seen with the use of PD-1 inhibitors in combination with ipilimumab, peptide vaccines, or chemotherapy than PD-1 inhibitor monotherapy.